Literature DB >> 23142988

Pattern of postoperative recurrence and hepatic and/or pulmonary resection for liver and/or lung metastases from esophageal carcinoma.

Hirofumi Ichida1, Hiroshi Imamura, Jiro Yoshimoto, Hiroyuki Sugo, Yoshiaki Kajiyama, Masahiko Tsurumaru, Kenji Suzuki, Yoichi Ishizaki, Seiji Kawasaki.   

Abstract

BACKGROUND: We assessed the benefit of hepatic and pulmonary resections in patients with liver and lung recurrences, respectively, after resection of esophageal carcinoma.
METHODS: The study population consisted of 138 consecutive patients with recurrent esophageal carcinoma after esophagectomy conducted between 2003 and 2005. The pattern, timing of appearance, and the prognosis of these recurrences were investigated, paying particular attention to those undergoing hepatic and pulmonary resections.
RESULTS: In total, 55 and 92 patients developed locoregional and distant-organ metastases 13 and 6 months (median) after surgery, respectively, including 9 patients with both types of recurrence. The distant-organ metastases were found in the liver (n = 26), lung (n = 27), bone (n = 21), and other organs (n = 29). Patients with pulmonary recurrences had a better overall prognosis (median survival after recurrence detection 13 months) than those with hepatic metastases (5 months) or nonhepatic nonpulmonary metastases. (3 months) Hepatic and pulmonary resections were carried out in patients with oligonodular (n = ≤ 2) isolated liver and lung metastases (n = 5, respectively). Although the survivals of patients with lung metastases who were treated/not treated by pulmonary resection were different (median survival: 48 vs. 10 months, p < 0.01), the difference in the survivals between patients with hepatic metastases who were treated/not treated by hepatic resection reached only borderline statistical significance (13 vs. 5 months, p = 0.06).
CONCLUSIONS: Resection of pulmonary metastases yields a survival benefit in properly selected patients. The benefit of resection for hepatic metastases remains controversial.

Entities:  

Mesh:

Year:  2013        PMID: 23142988     DOI: 10.1007/s00268-012-1830-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  26 in total

1.  Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.

Authors:  U Pastorino; M Buyse; G Friedel; R J Ginsberg; P Girard; P Goldstraw; M Johnston; P McCormack; H Pass; J B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  1997-01       Impact factor: 5.209

2.  Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma.

Authors:  Jürgen Weitz; Leslie H Blumgart; Yuman Fong; William R Jarnagin; Michael D'Angelica; Lawrence E Harrison; Ronald P DeMatteo
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

3.  Operative treatment for metachronous pulmonary metastasis from esophageal carcinoma.

Authors:  Hiroshi Ichikawa; Shin-ichi Kosugi; Satoru Nakagawa; Tatsuo Kanda; Masanori Tsuchida; Teruaki Koike; Otsuo Tanaka; Katsuyoshi Hatakeyama
Journal:  Surgery       Date:  2010-09-06       Impact factor: 3.982

4.  Cohort study of the survival benefit of resection for recurrent hepatic and/or pulmonary metastases after primary hepatectomy for colorectal metastases.

Authors:  Yoshihiro Mise; Hiroshi Imamura; Takuya Hashimoto; Yasuji Seyama; Taku Aoki; Kiyoshi Hasegawa; Yoshihumi Beck; Yasuhiko Sugawara; Masatoshi Makuuchi; Jun Nakajima; Norihiro Kokudo
Journal:  Ann Surg       Date:  2010-05       Impact factor: 12.969

Review 5.  Surgical treatment for metastatic malignancies. Pulmonary metastasis: indications and outcomes.

Authors:  Haruhiko Kondo; Takehiro Okumura; Yasuhisa Ohde; Kazuo Nakagawa
Journal:  Int J Clin Oncol       Date:  2005-04       Impact factor: 3.402

6.  Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis.

Authors:  Srinevas K Reddy; Andrew S Barbas; Carlos E Marroquin; Michael A Morse; Paul C Kuo; Bryan M Clary
Journal:  J Am Coll Surg       Date:  2007-03       Impact factor: 6.113

7.  Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.

Authors:  Juan M Sarmiento; Glenroy Heywood; Joseph Rubin; Duane M Ilstrup; David M Nagorney; Florencia G Que
Journal:  J Am Coll Surg       Date:  2003-07       Impact factor: 6.113

8.  Disease-free interval length correlates to prognosis of patients who underwent metastasectomy for esophageal lung metastases.

Authors:  Satoshi Shiono; Masafumi Kawamura; Toru Sato; Ken Nakagawa; Jun Nakajima; Ichiro Yoshino; Norihiko Ikeda; Hirotoshi Horio; Hirohiko Akiyama; Koichi Kobayashi
Journal:  J Thorac Oncol       Date:  2008-09       Impact factor: 15.609

Review 9.  Metastatic inefficiency: the scientific basis for resection of liver metastases from colorectal cancer.

Authors:  P H Sugarbaker
Journal:  J Surg Oncol Suppl       Date:  1993

10.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

View more
  18 in total

Review 1.  [Therapeutic approach in oligometastatic gastric and esophageal cancer].

Authors:  T Schmidt; S P Mönig
Journal:  Chirurg       Date:  2017-12       Impact factor: 0.955

2.  [Surgical therapy of lung metastases from head and neck cancer].

Authors:  S Macherey; S F Preuss; F Doerr; S Grönke; M Heldwein; A Quaas; T Zander; K Hekmat
Journal:  HNO       Date:  2014-12       Impact factor: 1.284

3.  Clinical Features of Recurrence Pattern with Lung Metastasis After Radical Esophagectomy for Thoracic Esophageal Cancer.

Authors:  Kazuaki Matsui; Hirofumi Kawakubo; Satoru Matsuda; Yuki Hirata; Tomoyuki Irino; Kazumasa Fukuda; Rieko Nakamura; Yuko Kitagawa
Journal:  World J Surg       Date:  2022-06-16       Impact factor: 3.282

4.  Patterns and Outcomes of Recurrent Esophageal Cancer After Curative Esophagectomy.

Authors:  Kotaro Yamashita; Masayuki Watanabe; Shinji Mine; Takanori Kurogochi; Akihiko Okamura; Masaru Hayami; Yu Imamura
Journal:  World J Surg       Date:  2017-09       Impact factor: 3.352

Review 5.  [Oligometastases in gastric and esophageal cancer : Current clinical trials and surgical concepts].

Authors:  S Beckert; A Königsrainer
Journal:  Chirurg       Date:  2018-07       Impact factor: 0.955

6.  The effect of tumor locations of esophageal cancer on the metastasis to liver or lung.

Authors:  Dashan Ai; Yun Chen; Qi Liu; Jiaying Deng; Kuaile Zhao
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

Review 7.  Role of surgical resection for non-colorectal non-neuroendocrine liver metastases.

Authors:  Nobuyuki Takemura; Akio Saiura
Journal:  World J Hepatol       Date:  2017-02-18

8.  Patterns of Distant Metastasis Between Histological Types in Esophageal Cancer.

Authors:  San-Gang Wu; Wen-Wen Zhang; Jia-Yuan Sun; Feng-Yan Li; Qin Lin; Zhen-Yu He
Journal:  Front Oncol       Date:  2018-08-08       Impact factor: 6.244

9.  Clinical impact of abdominal versus mediastinal metastases as a prognostic factor for poor outcomes following esophageal cancer surgery: a retrospective study.

Authors:  Yutaka Miyawaki; Hiroshi Sato; Shuichiro Oya; Hirofumi Sugita; Yasumitsu Hirano; Shinichi Sakuramoto; Kojun Okamotom; Shigeki Yamaguchim; Isamu Koyama
Journal:  BMC Cancer       Date:  2021-06-23       Impact factor: 4.430

Review 10.  The role of surgical treatment in isolated organ recurrence of esophageal cancer-a systematic review of the literature.

Authors:  Dimitrios Schizas; Ioannis I Lazaridis; Demetrios Moris; Aikaterini Mastoraki; Lazaros-Dimitrios Lazaridis; Diamantis I Tsilimigras; Nikolaos Charalampakis; Theodore Liakakos
Journal:  World J Surg Oncol       Date:  2018-03-14       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.